Börskollen - Aktier, fonder och ekonominyheter
Börskollen
•Sparande: Less på orolig börs? Här får du högsta sparräntan på 3,20 procent idag

Pressmeddelanden från ExpreS2ion Biotech

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts
27 feb 19:12
ExpreS2ion Biotech
Notice to convene Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)27 feb 19:10
ExpreS2ion Biotech
Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)27 feb 18:53
ExpreS2ion Biotech
EXPRES2ION ANNOUNCES THE BOARD OF DIRECTORS’ INTENTION TO RESOLVE ON A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 53 MILLION27 feb 14:32
ExpreS2ion Biotech
ExpreS2ion to Present at Sachs European Life Sciences CEO Forum and Økonomisk Ugebrev Life Science Investor Conference23 feb 14:00
ExpreS2ion Biotech
ExpreS2ion Provides Update on Investor Engagement Following Q4 and Full-Year 2025 Results19 feb 08:30
ExpreS2ion Biotech
ExpreS2ion Announces Financial Results for the Full-Year and Fourth Quarter of 202503 feb 14:47
ExpreS2ion Biotech
ExpreS2ion Biotech announces Redeye initiation of coverage with base case valuation of SEK 28 per share03 feb 10:54
ExpreS2ion Biotech
ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial of ES2B-C00128 jan 13:45
ExpreS2ion Biotech
As Nipah Virus Outbreaks in India Re-emerge, ExpreS2ion Selects Northway Biotech as Manufacturing Partner for Vaccine Program20 jan 14:00
ExpreS2ion Biotech
Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN19 jan 10:26
ExpreS2ion Biotech
ExpreS2ion to Participate in Key Investor Event in January 202619 dec 2025 11:45
ExpreS2ion Biotech
ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort13 nov 2025 08:30
ExpreS2ion Biotech
ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 202512 nov 2025 14:20
ExpreS2ion Biotech
Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines12 nov 2025 12:29
ExpreS2ion Biotech
ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines10 nov 2025 10:00
ExpreS2ion Biotech
Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases07 nov 2025 14:00
ExpreS2ion Biotech
ExpreS2ion Hereby Changes Certified Advisor to Redeye03 nov 2025 14:00
ExpreS2ion Biotech
ExpreS2ion to Participate in Key Investor and Industry Events in November 202508 okt 2025 14:00
ExpreS2ion Biotech
VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase06 okt 2025 16:12
ExpreS2ion Biotech
ExpreS2ion Biotechnologies: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors15 sep 2025 08:16
ExpreS2ion Biotech
ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding12 sep 2025 21:02
ExpreS2ion Biotech
ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period12 sep 2025 10:00
ExpreS2ion Biotech
ExpreS2ion to Present in Upcoming Investor Events04 sep 2025 08:45
ExpreS2ion Biotech
ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial02 sep 2025 11:00
ExpreS2ion Biotech
ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events27 aug 2025 15:15
ExpreS2ion Biotech
ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 7521 aug 2025 14:00
ExpreS2ion Biotech
ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 30321 aug 2025 08:30
ExpreS2ion Biotech
ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 202515 aug 2025 11:00
ExpreS2ion Biotech
ExpreS2ion to Present in Upcoming Investor Events18 jul 2025 11:50
ExpreS2ion Biotech
ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac07 jul 2025 10:10
ExpreS2ion Biotech
ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer30 jun 2025 14:57
ExpreS2ion Biotech
Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy24 jun 2025 16:15
ExpreS2ion Biotech
ExpreS2ion Biotech Announces Pareto Securities Analyst Note on First Patient Dosed in Phase I Trial23 jun 2025 14:03
ExpreS2ion Biotech
ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy19 jun 2025 09:39
ExpreS2ion Biotech
ExpreS2ion’s associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine28 maj 2025 11:30
ExpreS2ion Biotech
Bulletin from the Annual General Meeting of Expres2ion Biotech Holding AB held on 28 May 202523 maj 2025 13:29
ExpreS2ion Biotech
ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report21 maj 2025 11:13
ExpreS2ion Biotech
ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress15 maj 2025 08:30
ExpreS2ion Biotech
ExpreS2ion announces financial results for the first quarter of 202513 maj 2025 12:15
ExpreS2ion Biotech
ExpreS2ion files clinical trial amendment to enable combination testing of ES2B-C001 with antibody-drug conjugates and to expand the number of study sites09 maj 2025 13:00
ExpreS2ion Biotech
ExpreS2ion to Present in Upcoming Investor Events01 maj 2025 12:40
ExpreS2ion Biotech
ExpreS2ion annual report for 2024 published24 apr 2025 15:40
ExpreS2ion Biotech
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)24 apr 2025 15:39
ExpreS2ion Biotech
Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ)15 apr 2025 08:45
ExpreS2ion Biotech
ExpreS2ion signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™01 apr 2025 13:32
ExpreS2ion Biotech
ExpreS2ion Provides Pipeline Update31 mar 2025 17:40
ExpreS2ion Biotech
ExpreS2ion Announces Leadership Transition in R&D06 feb 2025 08:30
ExpreS2ion Biotech
ExpreS2ion announces financial results for the fourth quarter of 202409 jan 2025 11:00
ExpreS2ion Biotech
ExpreS2ion to Present in Upcoming Investor and Scientific Events11 dec 2024 12:10
ExpreS2ion Biotech
Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine11 dec 2024 10:00
ExpreS2ion Biotech
Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 9106 dec 2024 15:00
ExpreS2ion Biotech
Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million02 dec 2024 16:12
ExpreS2ion Biotech
ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer02 dec 2024 12:45
ExpreS2ion Biotech
ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna02 dec 2024 09:30
ExpreS2ion Biotech
Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 202421 nov 2024 08:45
ExpreS2ion Biotech
ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 1020 nov 2024 08:30
ExpreS2ion Biotech
ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 1018 nov 2024 11:00
ExpreS2ion Biotech
ExpreS2ion to present in upcoming investor and scientific events14 nov 2024 19:47
ExpreS2ion Biotech
ExpreS2ion announces TO 10 warrant exercise price and start of exercise period14 nov 2024 08:53
ExpreS2ion Biotech
Correction: ExpreS2ion announces financial results for the third quarter of 202414 nov 2024 08:30
ExpreS2ion Biotech
ExpreS2ion announces financial results for the third quarter of 202412 nov 2024 14:00
ExpreS2ion Biotech
ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I00205 nov 2024 15:21
ExpreS2ion Biotech
ExpreS2ion CEO talks to BioStock about partnering efforts at BIO-Europe05 nov 2024 08:15
ExpreS2ion Biotech
ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe04 nov 2024 11:00
ExpreS2ion Biotech
ExpreS2ion Biotech will present at the BioStock Life Science Summit, November 2104 nov 2024 11:00
ExpreS2ion Biotech
ExpreS2ion Biotech presenterar på BioStock Life Science Summit 21 november31 okt 2024 12:00
ExpreS2ion Biotech
ExpreS2ion to present in upcoming investor and scientific events24 okt 2024 12:00
ExpreS2ion Biotech
The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split21 okt 2024 11:00
ExpreS2ion Biotech
Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)16 okt 2024 13:17
ExpreS2ion Biotech
ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines19 sep 2024 09:15
ExpreS2ion Biotech
Notice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)19 sep 2024 09:15
ExpreS2ion Biotech
Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)10 sep 2024 14:00
ExpreS2ion Biotech
ExpreS2ion to present in upcoming investor events23 aug 2024 12:45
ExpreS2ion Biotech
ExpreS2ion announces publication of sponsored research reports15 aug 2024 08:30
ExpreS2ion Biotech
ExpreS2ion announces financial results for the second quarter of 202406 aug 2024 16:18
ExpreS2ion Biotech
ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine05 jul 2024 13:06
ExpreS2ion Biotech
ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue03 jul 2024 12:30
ExpreS2ion Biotech
ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens01 jul 2024 13:20
ExpreS2ion Biotech
ExpreS2ion announces final outcome of its rights issue26 jun 2024 09:00
ExpreS2ion Biotech
Rights issue subscription period ending 27 June 2024; subscription possible via form24 jun 2024 15:00
ExpreS2ion Biotech
ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting21 jun 2024 11:30
ExpreS2ion Biotech
Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine18 jun 2024 13:00
ExpreS2ion Biotech
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine14 jun 2024 08:45
ExpreS2ion Biotech
BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I12 jun 2024 09:15
ExpreS2ion Biotech
ExpreS2ion CEO to BioStock: “Compelling preclinical package gives us confidence”12 jun 2024 08:45
ExpreS2ion Biotech
The subscription period in ExpreS2ion’s rights issue begins today10 jun 2024 14:00
ExpreS2ion Biotech
ExpreS2ion to present in upcoming investor and scientific events05 jun 2024 16:40
ExpreS2ion Biotech
ExpreS2ion publishes prospectus in connection with its rights issue of units05 jun 2024 11:30
ExpreS2ion Biotech
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 202416 maj 2024 08:30
ExpreS2ion Biotech
ExpreS2ion announces financial results for the first quarter of 202415 maj 2024 15:17
ExpreS2ion Biotech
ExpreS2ion to present in spring investor events08 maj 2024 12:05
ExpreS2ion Biotech
ExpreS2ion annual report for 2023 published03 maj 2024 10:30
ExpreS2ion Biotech
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)03 maj 2024 10:30
ExpreS2ion Biotech
Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ)02 maj 2024 21:23
ExpreS2ion Biotech
ExpreS2ion announces a rights issue of units of approximately SEK 60 million23 apr 2024 14:20
ExpreS2ion Biotech
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS16 apr 2024 16:40
ExpreS2ion Biotech
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 202316 apr 2024 14:29
ExpreS2ion Biotech
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate15 apr 2024 15:00
ExpreS2ion Biotech
ExpreS2ion to present in investor and R&D events in March29 feb 2024 13:30
ExpreS2ion Biotech
ExpreS2ion to present in investor and R&D events in March